BacteremiaNCT05236283
Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland
An observational study of Bacteremia, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
Trial summary
The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bacteremia
- What is being tested?
- Blood Culture
- How many people
- 395 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Feb 2022to 30 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient is critically ill at the time the blood culture was collected and was treated at the ICU/IMC at the time of blood culture collection or has been admitted to ICU/IMC in the 48 hours after blood culture collection.
Who may be able to join
- Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:
- was treated at the ICU/IMC at the time of blood culture collection;
- or has been admitted to ICU/IMC in the 48 hours after blood culture collection
Who cannot join
- Patient has a single positive blood culture with a common contaminant organism:
- coagulase negative staphylococci;
- Bacillus spp.;
- Corynebacterium spp.;
- Propionibacterium spp.;
- Aerococcus spp.;
- Micrococcus spp.
- Explicit documentation that the patient does not want to participate in any study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Duration of Antimicrobial Treatment for Bloodstream Infections in Swiss Critically Ill Patients - Retrospective Double Center Study
The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.
- Conditions
- Bacteremia
- Being tested
- Blood Culture
- Medical subject headings
- Bacteremia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood CultureDiagnostic test
Blood Culture
| Study group | Role | What they receive |
|---|---|---|
| Bern ICU | Not described Receives: Diagnostic Test: Blood Culture | |
| Lausanne ICU | Not described Receives: Diagnostic Test: Blood Culture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antibiotic Treatment Duration
Days of adequate antibiotic treatment in Patients with Bacteremia
Measured: Hospital discharge, expected to be on average ca. 15-20 days
Secondary outcomes (2)
Days of ICU stay
Days of ICU Stay in Patients with Bacteremia
Measured: ICU discharge, expected to be on average ca. 5-15 days
Days of hospital stay
Days of Inhospital Stay in Patients with Bacteremia
Measured: Hospital discharge, expected to be on average ca. 15-25 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2022
- Study start1 Feb 2022
- Primary completion1 Mar 2022
- Study completion30 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for BacteremiaStudies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 395 participants (actual)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Josef Prazak, MD, PhD, Principal investigator, Insel Gruppe AG, University Hospital Bern
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05236283
- Sponsor's protocol ID
- 2021-02302
- Status last verified
- Jan 2023
- First submitted
- 1 Feb 2022
- Last updated
- 26 Jan 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Zuercher P, Moser A, Frey MC, Pagani JL, Buetti N, Eggimann P, Daneman N, Fowler R, Que YA, Prazak J. The effect of duration of antimicrobial treatment for bacteremia in critically ill patients on in-hospital mortality - Retrospective double center analysis. J Crit Care. 2023 Apr;74:154257. doi: 10.1016/j.jcrc.2023.154257. Epub 2023 Jan 23.
PubMed 36696827
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Duration of Antimicrobial Treatment for Bloodstream Infections in Swiss Critically Ill Patients - Retrospective Double Center Study
- ClinicalTrials.gov ID
- NCT05236283
- Acronym / sponsor ID
- 2021-02302
- Conditions
- Bacteremia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 395 participants (actual)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 1 Mar 2022 (actual)
- Study completion
- 30 Mar 2022 (actual)
- First posted
- 11 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bern ICU | – | Diagnostic Test: Blood Culture |
| Lausanne ICU | – | Diagnostic Test: Blood Culture |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient is critically ill at the time the blood culture was collected and was treated at the ICU/IMC at the time of blood culture collection or has been admitted to ICU/IMC in the 48 hours after blood culture collection.
Key inclusion criteria (3 listed)
- Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:
- was treated at the ICU/IMC at the time of blood culture collection;
- or has been admitted to ICU/IMC in the 48 hours after blood culture collection
Key exclusion criteria (8 listed)
- Patient has a single positive blood culture with a common contaminant organism:
- Explicit documentation that the patient does not want to participate in any study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood CultureBlood Culture | Diagnostic test | Bern ICU, Lausanne ICU |
Primary outcome
Antibiotic Treatment Duration
Time frame: Hospital discharge, expected to be on average ca. 15-20 days
Days of adequate antibiotic treatment in Patients with Bacteremia
2 secondary outcomes
Days of ICU stay
Time frame: ICU discharge, expected to be on average ca. 5-15 days
Days of hospital stay
Time frame: Hospital discharge, expected to be on average ca. 15-25 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2023.
- Derived from this study: PubMed 36696827Zuercher P, Moser A, Frey MC, Pagani JL, Buetti N, Eggimann P, Daneman N, Fowler R, Que YA, Prazak J. The effect of duration of antimicrobial treatment for bacteremia in critically ill patients on in-hospital mortality - Retrospective double center analysis. J Crit Care. 2023 Apr;74:154257. doi: 10.1016/j.jcrc.2023.154257. Epub 2023 Jan 23.
Related trials for Bacteremia
RecruitingObservational study
Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia
Bacteria Infection Mechanism
Not yet recruitingPhase 4
Oral Switch in Bloodstream Infections in Immunocompromised Children
Bloodstream Infection, Bloodstream Infection Due to Central Venous Catheter
Not yet recruiting
Evaluation of an AI-Assisted Tool for CLABSI Surveillance at VA Medical Centers
Central Line-Associated Bloodstream Infection (CLABSI), Bacteremia
RecruitingPhase 2
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
RecruitingObservational study
Middle East Study of Infections in Patients With Hematological Malignancies
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Josef Prazak, MD, PhD principal investigator
Insel Gruppe AG, University Hospital Bern
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bacteremia, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antibiotic Treatment Duration (time frame: Hospital discharge, expected to be on average ca. 15-20 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05236283, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2023.